Q2 Earnings Estimate for Biofrontera Issued By Roth Capital

Biofrontera Inc. (NASDAQ:BFRI) – Stock analysts at Roth Capital issued their Q2 2025 EPS estimates for Biofrontera in a research report issued on Thursday, November 14th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings per share of ($0.32) for the quarter. The consensus estimate for Biofrontera’s current full-year earnings is ($3.11) per share. Roth Capital also issued estimates for Biofrontera’s Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at $0.12 EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.34 EPS and FY2028 earnings at $0.63 EPS.

Separately, Benchmark reiterated a “buy” rating and issued a $7.00 price target on shares of Biofrontera in a research note on Friday.

Biofrontera Price Performance

Shares of NASDAQ:BFRI opened at $0.73 on Monday. The business’s 50 day simple moving average is $1.02 and its 200 day simple moving average is $1.09. Biofrontera has a 1 year low of $0.61 and a 1 year high of $4.04.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.